Detalhe da pesquisa
1.
Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity.
Eur J Haematol
; 112(4): 516-529, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994576
2.
Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data.
Eur J Haematol
; 111(1): 72-83, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965105
3.
Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH.
Health Qual Life Outcomes
; 21(1): 113, 2023 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37838660
4.
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Ann Hematol
; 101(2): 251-263, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34973099
5.
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.
Ann Hematol
; 101(9): 1905-1914, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869984
6.
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.
Eur J Haematol
; 109(4): 351-363, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35746830
7.
Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System.
J Ment Health Policy Econ
; 24(2): 47-59, 2021 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34151777
8.
Time course of drug-related treatment-emergent adverse side effects of brivaracetam.
Epilepsy Behav
; 111: 107212, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32544700
9.
Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States.
Epilepsy Behav
; 99: 106331, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31399339
10.
Innovative approaches reaching underserved and rural communities to improve epilepsy care: A review of the methodology of the Connectors Project.
Epilepsy Behav
; 90: 273-283, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30391149
11.
Current state of the union of epilepsy care in the United States: Antiepileptic drugs - An introduction to the Connectors Project.
Epilepsy Behav
; 80: 98-103, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29414565
12.
Patient emotions and perceptions of antiepileptic drug changes and titration during treatment for epilepsy.
Epilepsy Behav
; 69: 44-52, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222341
13.
Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks.
J Clin Med
; 13(6)2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38541928
14.
Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
Adv Ther
; 41(1): 413-430, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37999832
15.
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests.
J Health Econ Outcomes Res
; 11(1): 32-43, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38370007
16.
Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment.
Hematol Rep
; 15(4): 578-591, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37873795
17.
Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network.
Hematol Rep
; 15(2): 266-282, 2023 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37092521
18.
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.
Pharmacoecon Open
; 7(1): 93-110, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36104546
19.
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria.
J Manag Care Spec Pharm
; 29(8): 941-951, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523317
20.
The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.
J Comp Eff Res
; 12(10): e230055, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37655691